HuaKe Run Secures RMB 60 Million in Series A Funding

Recently, Hicren Biotechnology Co., Ltd. of Ningbo, an innovative domestic company in the field of minimally invasive spinal surgery, completed a RMB 60 million Series A funding round, which was exclusively led by Jinpu Health Fund.

Huake Run is dedicated to the R&D, manufacturing, and sales of innovative medical devices in the field of minimally invasive spinal surgery. Its product portfolio—including bone cement delivery kits, percutaneous puncture needles, and medical irrigation devices—has already obtained regulatory approvals and been successfully launched on the market, with several additional product lines slated for approval and market launch this year. The company has successfully achieved product serialization for advanced vertebral augmentation procedures, becoming the first domestic manufacturer to receive CFDA approval for the commercialization of a curved-angle vertebral augmentation instrument series.

Since its inception, Huake Run has aspired to become an internationally oriented medical-device manufacturer—this is both the company’s ultimate goal and its guiding principle for development. From the very beginning, the company has been steadily expanding its patent portfolio at a rate of more than a dozen new patents per year, with patents now spanning the globe, thereby demonstrating its robust R&D and innovation capabilities. In 2012, a company project received funding under the Ningbo Municipal Science and Technology Bureau’s Smart Innovation Program; in 2013, the company was recognized as an Innovation Team in the Hangzhou Bay New Area; in 2015, it secured major industrial project funding from the Ningbo Municipal Science and Technology Bureau; and in 2017, it was approved to establish the Ningbo Huake Run District-level Engineering Technology Center. Furthermore, at the WOISE 2017 World Orthopedic Innovation Conference, Huake Run was awarded the only “Best Innovative Orthopedic Device Award” in the orthopedic device category, presented in person by Academician Dai Kerong. That same year, the company’s products also took second place in the “6th China Innovation and Entrepreneurship Competition.”

About the Gimpo Health Fund

Shanghai Jinpu Healthcare Equity Investment Partnership (Limited Partnership), commonly referred to as the “Jinpu Healthcare Fund,” is a specialized fund management firm under Jinpu Investment that focuses on equity investments in the healthcare sector. Its investment areas encompass biotechnology and pharmaceuticals, medical devices, mobile health, and healthcare services. The Jinpu Healthcare Fund conducts in-depth exploration across the upstream and downstream segments of the healthcare value chain, positioning itself as a value discoverer by making early-stage commitments to high-potential projects, providing end-to-end oversight, facilitating resource integration for portfolio companies, and enhancing their enterprise value—thereby becoming a value creator. Guided by national strategies for industrial restructuring and upgrading, the fund concentrates on building a comprehensive footprint within the healthcare industry chain, leveraging a global perspective to identify and pursue investment opportunities while adopting a full-chain investment approach that spans angel investing, venture capital, private equity, New Third Board listings, M&A transactions, and PIPE financing. Upholding this investment philosophy, the fund is committed to establishing China’s premier brand in healthcare equity investment, thereby driving the sustained development and advancement of China’s healthcare industry.